BioAlliance Pharma said that plasmid AMEP displays anti-angiogenic and anti-metastatic properties. Results presented describe the anti-angiogenic and anti-tumoral properties of the plasmid AMEP biotherapy in in vitro and in vivo models, said BioAlliance Pharma.
In an in vivo experimental model of invasive melanoma, tumor treatment by plasmid AMEP biotherapy, applied through either intratumoral or intramuscular route, induced a strong tumor growth inhibition (>95% and >50%, respectively), according to the company. Moreover, preliminary acute toxicology studies show that plasmid AMEP biotherapy is safe and well-tolerated, the company added.
It is reported that preclinical toxicology and biodistribution regulatory studies are in progress and will allow the submission of the regulatory file for a Phase I clinical trial planned in 2009 in metastatic melanoma patients.